These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 9733946)
21. SoRI 9409, a non-peptide opioid mu receptor agonist/delta receptor antagonist, fails to stimulate [35S]-GTP-gamma-S binding at cloned opioid receptors. Xu H; Lu YF; Rice KC; Ananthan S; Rothman RB Brain Res Bull; 2001 Jul; 55(4):507-11. PubMed ID: 11543951 [TBL] [Abstract][Full Text] [Related]
22. The effect of chronic treatment with naltrindole, a selective delta-opioid antagonist, on mu-opioid receptor-mediated antinociception in diabetic mice. Kamei J; Kawashima N; Iwamoto Y; Suzuki T; Nagase H; Misawa M; Kasuya Y Psychopharmacology (Berl); 1993; 113(2):167-71. PubMed ID: 7855177 [TBL] [Abstract][Full Text] [Related]
23. mu/delta Cooperativity and opposing kappa-opioid effects in nucleus accumbens-mediated antinociception in the rat. Schmidt BL; Tambeli CH; Levine JD; Gear RW Eur J Neurosci; 2002 Mar; 15(5):861-8. PubMed ID: 11906528 [TBL] [Abstract][Full Text] [Related]
24. Different roles of mu-, delta- and kappa-opioid receptors in ethanol-associated place preference in rats exposed to conditioned fear stress. Matsuzawa S; Suzuki T; Misawa M; Nagase H Eur J Pharmacol; 1999 Feb; 368(1):9-16. PubMed ID: 10096764 [TBL] [Abstract][Full Text] [Related]
25. Involvement of mu-, delta- and kappa-opioid receptor subtypes in the discriminative-stimulus effects of delta-9-tetrahydrocannabinol (THC) in rats. Solinas M; Goldberg SR Psychopharmacology (Berl); 2005 Jun; 179(4):804-12. PubMed ID: 15619107 [TBL] [Abstract][Full Text] [Related]
26. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence. Wells JL; Bartlett JL; Ananthan S; Bilsky EJ J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048 [TBL] [Abstract][Full Text] [Related]
27. Antitussive effects of naltrindole, a selective delta-opioid receptor antagonist, in mice and rats. Kamei J; Iwamoto Y; Suzuki T; Misawa M; Nagase H; Kasuya Y Eur J Pharmacol; 1993 Nov; 249(2):161-5. PubMed ID: 8287897 [TBL] [Abstract][Full Text] [Related]
28. Neonatal naltrindole and handling differently affect morphine antinociception in male and female rats. Fernández B; Alberti I; Kitchen I; Viveros MP Pharmacol Biochem Behav; 1999 Dec; 64(4):851-5. PubMed ID: 10593209 [TBL] [Abstract][Full Text] [Related]
29. Antinociceptive and behavioral effects of synthetic deltorphin analogs. Negri L; Noviello L; Noviello V Eur J Pharmacol; 1996 Jan; 296(1):9-16. PubMed ID: 8720471 [TBL] [Abstract][Full Text] [Related]
30. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety. Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975 [TBL] [Abstract][Full Text] [Related]
31. Behavioral effects of benzylideneoxymorphone (BOM), a low efficacy µ opioid receptor agonist and a δ opioid receptor antagonist. Mada S; Gerak LR; Soyer A; Maguire DR; Hu Z; Minervini V; Cunningham CW; France CP Psychopharmacology (Berl); 2020 Dec; 237(12):3591-3602. PubMed ID: 32820390 [TBL] [Abstract][Full Text] [Related]
32. Exploring delta-receptor function using the selective opioid antagonist naltrindole. Jackson HC; Ripley TL; Nutt DJ Neuropharmacology; 1989 Dec; 28(12):1427-30. PubMed ID: 2559353 [TBL] [Abstract][Full Text] [Related]
33. The effects of intravenous naltrindole and naltrindole 5'-isothiocyanate on sufentanil-induced respiratory depression and antinociception in rats. Verborgh C; Meert TF Pharmacol Biochem Behav; 1999 May; 63(1):175-83. PubMed ID: 10340539 [TBL] [Abstract][Full Text] [Related]
34. Use of selective antagonists and antisense oligonucleotides to evaluate the mechanisms of BUBU antinociception. Hutcheson DM; Sánchez-Blazquez P; Rodriguez-Diaz M; Garzon J; Schmidhammer H; Borsodi A; Roques BP; Maldonado R Eur J Pharmacol; 1999 Oct; 383(1):29-37. PubMed ID: 10556678 [TBL] [Abstract][Full Text] [Related]
35. Delta-opiod receptor-mediated forced swimming stress-induced antinociception in the formalin test. Kamei J; Hitosugi H; Misawa M; Nagase H; Kasuya Y Psychopharmacology (Berl); 1993; 113(1):15-8. PubMed ID: 7862822 [TBL] [Abstract][Full Text] [Related]
36. Suppression of ethanol responding by centrally administered CTOP and naltrindole in AA and Wistar rats. Hyytiä P; Kiianmaa K Alcohol Clin Exp Res; 2001 Jan; 25(1):25-33. PubMed ID: 11198711 [TBL] [Abstract][Full Text] [Related]
37. Comparison of receptor mechanisms and efficacy requirements for delta-agonist-induced convulsive activity and antinociception in mice. Broom DC; Nitsche JF; Pintar JE; Rice KC; Woods JH; Traynor JR J Pharmacol Exp Ther; 2002 Nov; 303(2):723-9. PubMed ID: 12388657 [TBL] [Abstract][Full Text] [Related]
38. A comparison of the effects of the opioid antagonists naltrexone, naltrindole, and beta-funaltrexamine on ethanol consumption in the rat. Stromberg MF; Casale M; Volpicelli L; Volpicelli JR; O'Brien CP Alcohol; 1998 May; 15(4):281-9. PubMed ID: 9590512 [TBL] [Abstract][Full Text] [Related]
39. Stress-induced analgesia in mu-opioid receptor knockout mice reveals normal function of the delta-opioid receptor system. LaBuda CJ; Sora I; Uhl GR; Fuchs PN Brain Res; 2000 Jun; 869(1-2):1-5. PubMed ID: 10865052 [TBL] [Abstract][Full Text] [Related]
40. Activity of mu- and delta-opioid agonists in vas deferens from mice deficient in MOR gene. Maldonado R; Severini C; Matthes HW; Kieffer BL; Melchiorri P; Negri L Br J Pharmacol; 2001 Apr; 132(7):1485-92. PubMed ID: 11264242 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]